Angiogenesis inhibitors for metastatic colorectal cancer.

Per Pfeiffer, Gabor Liposits, Line Schmidt Taarpgaard
Author Information
  1. Per Pfeiffer: Department of Oncology, Odense University Hospital, Odense, Denmark.
  2. Gabor Liposits: Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  3. Line Schmidt Taarpgaard: Department of Oncology, Odense University Hospital, Odense, Denmark.

Abstract

No abstract text available.

Keywords

References

  1. J Natl Cancer Inst. 2014 Feb;106(2):djt371 [PMID: 24511107]
  2. Lancet Oncol. 2020 Mar;21(3):412-420 [PMID: 31999946]
  3. Eur J Cancer. 2019 Jan;106:37-44 [PMID: 30476731]
  4. Cancers (Basel). 2021 Mar 01;13(5): [PMID: 33804554]
  5. N Engl J Med. 2023 May 4;388(18):1657-1667 [PMID: 37133585]
  6. JAMA. 2018 Jun 26;319(24):2486-2496 [PMID: 29946728]
  7. BMC Cancer. 2016 Aug 24;16:677 [PMID: 27558497]
  8. Lancet. 2023 Jul 1;402(10395):41-53 [PMID: 37331369]
  9. PLoS One. 2015 Jun 29;10(6):e0131046 [PMID: 26121270]
  10. Ann Oncol. 2016 Aug;27(8):1386-422 [PMID: 27380959]
  11. Transl Cancer Res. 2023 May 31;12(5):1067-1072 [PMID: 37304531]
  12. N Engl J Med. 2015 May 14;372(20):1909-19 [PMID: 25970050]
  13. Lancet. 2013 Jan 26;381(9863):303-12 [PMID: 23177514]
  14. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  15. N Engl J Med. 1971 Nov 18;285(21):1182-6 [PMID: 4938153]
  16. Ann Oncol. 2023 Jan;34(1):10-32 [PMID: 36307056]

Word Cloud

Created with Highcharts 10.0.0inhibitorscancerAngiogenesismetastaticcolorectalColorectalCRCangiogenesisfruquintinib

Similar Articles

Cited By